APPENDIX

AMENDMENT TO THE CLAIMS

Claim 1 (Currently amended): A composition for prevention, amelioration or control of external parasites on animals and humans comprising a pharmaceutically acceptable carrier and an ectoparasiticidally effective amount of a compound of formula I



(I)

or a pharmaceutically acceptable salt thereof wherein

R is halogen, OR_7, SO_mR_8, NO_2, CN, C_1-C_6haloalkyl or an optionally substituted C_1-C_6 alkyl group;

n is 0 or an integer of 1, 2 or 3;

m is 0 or an integer of 1 or 2;

R_1 is H, halogen, NO_2, NR_9R_{10}, $NR_{11}COR_{12}$, $NCHNR_9R_{10}$ or $NCHOR_{13}$;

R_2, R_3, R_4, R_5 and R_6 are each independently H, halogen or a C_1-C_4alkyl, aryl or heteroaryl group each optionally substituted;

R_7 is H or a C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, aryl or heteroaryl group each optionally substituted;

R_8 is a C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, aryl or heteroaryl group, each optionally substituted;

R_9 and R_{10} are each independently H, C_1-C_4haloalkyl or a C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, aryl or heteroaryl group each optionally substituted or R_9 and R_{10} may be taken together with the atom to which they are attached to form a 5- to 7-membered ring optionally containing 1 or 2 additional heteroatoms selected from O, N or S;

R_{11} is H, COR_{12} or an optionally substituted C_1-C_4alkyl group;

R_{12} is a C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, aryl or heteroaryl group each optionally substituted; and

R_{13} is H or a C_1-C_6alkyl, aryl or heteroaryl group each optionally substituted; or a stereoisomer or tautomer thereof;

~~provided that R_3, R_4, R_5 and R_6 are not all –H, unless R_1 is halogen; and provided further that when R_1 is hydrogen, halogen or NH_2, R_2 is C_1-C_4 alkyl, R_3 and R_4 are both halogen and R_5 and R_6 are both hydrogen, then $(R)_n$ cannot be 2,6-dihalo-4-trifluoromethyl~~ .

Claim 2 (Canceled).

Claim 3 (Currently amended): The composition according to claim ~~2~~ 1 wherein R is halogen or haloalkyl.

Claim 4 (Currently amended): The composition according to claim ~~2~~ 1 wherein R_1 is H, halogen or NR_9R_{10}.

Claim 5 (Original): The composition according to claim 1 wherein R_5 and R_6 are H.

Claim 6 (Original): The composition according to claim 3 wherein R_2 is H, halogen, methyl or an optionally substituted phenyl group.

Claim 7 (Original): The composition according to claim 6 wherein R_1 is H or Cl.

Claim 8 (Original): The composition according to claim 7 wherein R is halogen or CF_3 and n is 3.

Claim 9 (Original): The composition according to claim 8 wherein R_2 is Cl or methyl and R_3 and R_4 are each independently H, Cl or Br.

Claim 10 (Currently amended): The composition according to claim ~~2~~ 1 wherein said compound is selected from the group consisting of:

~~5-chloro-3-(2,2-dichloro-1methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;~~

~~3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;~~

3-(2,2-dichloro-1-methylcyclopropyl)-1-(2,4,6-trichlorophenyl)-1H-pyrazole-4-carbonitrile;

3-(2,2-dichloro-1,3-dimethylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;

~~3-(2,2-dibromo-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;~~

3-(2,2-dibromo-1-methylcyclopropyl)-1-(2,4,6-trichlorophenyl)-1H-pyrazole-4-carbonitrile;

3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;

~~5-chloro-3-(2,2-dibromo-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl-1H-pyrazole-4-carbonitrile;~~

~~5-amino-3-(2,2-dibromo-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl-1H-pyrazole-4-carbonitrile;~~

~~5-bromo-3-(2,2-dibromo-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;~~

5-amino-3-(2,2-dichloro-1-methylcyclopropyl)-1-(2,4,6-trichlorophenyl)-1H-pyrazole-4-carbonitrile;

5-chloro-3-cyclopropyl-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;

~~5-chloro-3-cyclopropyl-1-[2,6-dichloro-4-(trifluoromethyl)phenyl-1H-pyrazole-4-carbonitrile;~~

5-chloro-3-(2,2-dichloro-1-methylcyclopropyl)-1-(2,4,6-trichlorophenyl)-1H-pyrazole-4-carbonitrile;

5-bromo-3-(2,2-dichloro-1-methylcyclopropyl)-1-(2,4,6-trichlorophenyl)-1H-pyrazole-4-carbonitrile;

~~5-bromo-3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;~~

3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-5-nitro-1H-pyrazole-4-carbonitrile;

3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-5-iodo-1H-pyrazole-4-carbonitrile;

3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-5-(dimethylamino)-1H-pyrazole-4-carbonitrile;

3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-5-(diethylamino)-1H-pyrazole-4-carbonitrile;

~~3-(2,2-dichloro-1-methylcyclopyrazol)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-5-(diethylamino)-1H-pyrazole-4-carbonitrile;~~

5-[(cyclopropanecarbonyl)amino]-3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;

~~5-[(cyclopropanecarbonyl)amino-]-3-(2,2-dichloro-1methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;~~

N-{4-cyano-5-(2,2-dichloro-1-methyl-cyclopropyl)-2-[2,6-dichloro-4-(trifluoromethyl)-phenyl]-2H-pyrazol-3-yl}-formimidic acid methyl ester;

N-{4-cyano-5-(2,2-dichloro-1-methyl-cyclopropyl)-2-[2,6-dichloro-4-(trifluoromethyl)-phenyl]-2-H-pyrazol-3-yl}-formimidic acid propyl ester;

N-{4-cyano-5-(2,2-dichloro-1-methyl-cyclopropyl)-2-[2,6-dichloro-4-(trifluoromethyl)-phenyl]-2H-pyrazol-3-yl}-formimidic acid ethyl ester; and

~~the stereoisomers thereof; and the tautomers thereof; or a~~ the stereoisomer, the tautomer and the pharmaceutically acceptable salt thereof.

Claims 11-19 (Canceled).

Claims 20-23 (Canceled).

Claim 24 (Currently amended): A veterinary pour-on composition which comprises: approximately 40-50% by weight xylene; approximately 20-30% by weight cyclohexanone;

approximately 5-15% vegetable or mineral oil or a combination thereof; and approximately 10-25% of a compound selected from the group consisting of:

5-chloro-3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;

5-chloro-3-(2,2-dichloro-1methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;

3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;

3-(2,2-dichloro-1-methylcyclopropyl)-1-(2,4,6-trichlorophenyl)-1H-pyrazole-4-carbonitrile;

3-(2,2-dichloro-1,3-dimethylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;

3-(2,2-dibromo-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;

3-(2,2-dibromo-1-methylcyclopropyl)-1-(2,4,6-trichlorophenyl)-1H-pyrazole-4-carbonitrile;

3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;

5-chloro-3-(2,2-dibromo-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;

5-chloro-3-(2,2-dibromo-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl-1H-pyrazole-4-carbonitrile;

5-amino-3-(2,2-dibromo-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;

5-amino-3-(2,2-dibromo-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl-1H-pyrazole-4-carbonitrile;

5-bromo-3-(2,2-dibromo-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;

5-amino-3-(2,2-dichloro-1-methylcyclopropyl)-1-(2,4,6-trichlorophenyl)-1H-pyrazole-4-carbonitrile;

5-chloro-3-cyclopropyl-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;

5-chloro-3-cyclopropyl-1--[2,6-dichloro-4-(trifluoromethyl)phenyl-1H-pyrazole-4-carbonitrile;

5-chloro-3-(2,2-dichloro-1-methylcyclopropyl)-1-(2,4,6-trichlorophenyl)-1H-pyrazole-4-carbonitrile;

5-bromo-3-(2,2-dichloro-1-methylcyclopropyl)-1-(2,4,6-trichlorophenyl)-1H-pyrazole-4-carbonitrile;

5-bromo-3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;

3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-5-nitro-1H-pyrazole-4-carbonitrile;

3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-5-iodo-1H-pyrazole-4-carbonitrile;

3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-5-(dimethylamino)-1H-pyrazole-4-carbonitrile;

3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-5-(diethylamino)-1H-pyrazole-4-carbonitrile;

~~3-(2,2-dichloro-1-methylcyclopyrazol)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-5-(diethylamino)-1H-pyrazole-4-carbonitrile;~~

5-[(cyclopropanecarbonyl)amino]-3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;

~~5-[(cyclopropanecarbonyl)amino-]-3-(2,2-dichloro-1methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;~~

N-{4-cyano-5-(2,2-dichloro-1-methyl-cyclopropyl)-2-[2,6-dichloro-4-(trifluoromethyl)-phenyl]-2H-pyrazol-3-yl}-formimidic acid methyl ester;

N-{4-cyano-5-(2,2-dichloro-1-methyl-cyclopropyl)-2-[2,6-dichloro-4-(trifluoromethyl)-phenyl]-2-H-pyrazol-3-yl}-formimidic acid propyl ester;

N-{4-cyano-5-(2,2-dichloro-1-methyl-cyclopropyl)-2-[2,6-dichloro-4-(trifluoromethyl)-phenyl]-2-H-pyrazol-3-yl}-formimidic acid ethyl ester; and

~~the stereoisomers thereof; and the tautomers thereof~~ the stereoisomer, the tautomer and the pharmaceutically acceptable salt thereof.

Claim 25 (Original): The composition according to claim 24 wherein an effective dosage of said compound is within the range of about 0.1 mg/kg to 100 mg/kg of animal body weight.

Claim 26 (Currently amended): A veterinary composition which comprises a pharmaceutically acceptable carrier and about 0.1 ppm to 5000 ppm of a compound selected from the group consisting of:

~~5-chloro-3-(2,2-dichloro-1methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;~~

~~3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;~~

3-(2,2-dichloro-1-methylcyclopropyl)-1-(2,4,6-trichlorophenyl)-1H-pyrazole-4-carbonitrile;

3-(2,2-dichloro-1,3-dimethylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;

~~3-(2,2-dibromo-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;~~

3-(2,2-dibromo-1-methylcyclopropyl)-1-(2,4,6-trichlorophenyl)-1H-pyrazole-4-carbonitrile;

3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;

~~5-chloro-3-(2,2-dibromo-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl-1H-pyrazole-4-carbonitrile;~~

~~5-amino-3-(2,2-dibromo-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl-1H-pyrazole-4-carbonitrile;~~

~~5-bromo-3-(2,2-dibromo-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;~~

5-amino-3-(2,2-dichloro-1-methylcyclopropyl)-1-(2,4,6-trichlorophenyl)-1H-pyrazole-4-carbonitrile;

5-chloro-3-cyclopropyl-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;

~~5-chloro-3-cyclopropyl-1--[2,6-dichloro-4-(trifluoromethyl)phenyl-1H-pyrazole-4-carbonitrile;~~

5-chloro-3-(2,2-dichloro-1-methylcyclopropyl)-1-(2,4,6-trichlorophenyl)-1H-pyrazole-4-carbonitrile;

5-bromo-3-(2,2-dichloro-1-methylcyclopropyl)-1-(2,4,6-trichlorophenyl)-1H-pyrazole-4-carbonitrile;

~~5-bromo-3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;~~

3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-5-nitro-1H-pyrazole-4-carbonitrile;

3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-5-iodo-1H-pyrazole-4-carbonitrile;

3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-5-(dimethylamino)-1H-pyrazole-4-carbonitrile;

3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-5-(diethylamino)-1H-pyrazole-4-carbonitrile;

~~3-(2,2-dichloro-1-methylcyclopyrazol)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-5-(diethylamino)-1H-pyrazole-4-carbonitrile;~~

5-[(cyclopropanecarbonyl)amino]-3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;

~~5-[(cyclopropanecarbonyl)amino-]-3-(2,2-dichloro-1methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;~~

N-{4-cyano-5-(2,2-dichloro-1-methyl-cyclopropyl)-2-[2,6-dichloro-4-(trifluoromethyl)-phenyl]-2H-pyrazol-3-yl}-formimidic acid methyl ester;

N-{4-cyano-5-(2,2-dichloro-1-methyl-cyclopropyl)-2-[2,6-dichloro-4-(trifluoromethyl)-phenyl]-2-H-pyrazol-3-yl}-formimidic acid propyl ester;

N-{4-cyano-5-(2,2-dichloro-1-methyl-cyclopropyl)-2-[2,6-dichloro-4-(trifluoromethyl)-phenyl]-2-H-pyrazol-3-yl}-formimidic acid ethyl ester; and

~~the stereoisomers thereof, and the tautomers thereof~~ the stereoisomer, the tautomer and the pharmaceutically acceptable salt thereof.

Claim 27 (Original): The composition according to claim 26 which comprises about 0.5 ppm to 1000 ppm of said compound.

Claim 28 (Original): The composition according to claim 27 which comprises about 0.2 ppm to 20 ppm of said compound.

Claim 29 (Currently amended): A compound of formula I



(I)

or a pharmaceutically acceptable salt thereof wherein

R is halogen, OR_7, SO_mR_8, NO_2, CN, C_1-C_6haloalkyl or an optionally substituted C_1-C_6alkyl group;

n is 0 or an integer of 1, 2 or 3;

m is 0 or an integer of 1 or 2;

R_1 is H, halogen, NO_2, NR_9R_{10}, $NR_{11}COR_{12}$, $NCHNR_9R_{10}$ or $NCHOR_{13}$;

R_2, R_3, R_4, R_5 and R_6 are each independently H, halogen or a C_1-C_4alkyl, aryl or heteroaryl group each optionally substituted;

R_7 is H or a C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, aryl or heteroaryl group each optionally substituted;

R_8 is a C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, aryl or heteroaryl group, each optionally substituted;

R_9 and R_{10} are each independently H, C_1-C_4haloalkyl or a C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, aryl or heteroaryl group each optionally substituted or R_9 and R_{10} may be taken together with the atom to which they are attached to form a 5- to 7-membered ring optionally containing 1 or 2 additional heteroatoms selected from O, N or S;

R_{11} is H, COR_{12} or an optionally substituted C_1-C_4alkyl group;

R_{12} is a C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, aryl or heteroaryl group each optionally substituted; and

R_{13} is H or a C_1-C_6alkyl, aryl or heteroaryl group each optionally substituted; or a stereoisomer or tautomer thereof;

provided that R_3, R_4, R_5 and R_6 are not all –H, unless R_1 is halogen; and provided further that when R_1 is hydrogen, halogen or NH_2, R_2 is C_1-C_4 alkyl, R_3 and R_4 are both halogen and R_5 and R_6 are both hydrogen, then $(R)_n$ cannot be 2,6-dihalo-4-trifluoromethyl.

Claim 30 (Canceled).

Please add new Claims 31-35 as follows:

Claim 31 (New): A veterinary pour-on composition which comprises: a spreading oil, an aliphatic or aromatic hydrocarbon, mono or polyhydric alcohol, a C_1-C_{10} alkyl ketone, or a mixture thereof; and an ectoparasiticidally effective amount of a compound of formula I



(I)

or a pharmaceutically acceptable salt thereof wherein

R is halogen, OR_7, SO_mR_8, NO_2, CN, C_1-C_6haloalkyl or an optionally substituted C_1-C_6alkyl group;

n is 0 or an integer of 1, 2 or 3;

m is 0 or an integer of 1 or 2;

R_1 is H, halogen, NO_2, NR_9R_{10}, $NR_{11}COR_{12}$, $NCHNR_9R_{10}$ or $NCHOR_{13}$;

R_2, R_3, R_4, R_5 and R_6 are each independently H, halogen or a C_1-C_4alkyl, aryl or heteroaryl group each optionally substituted;

R_7 is H or a C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, aryl or heteroaryl group each optionally substituted;

R_8 is a C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, aryl or heteroaryl group, each optionally substituted;

R_9 and R_{10} are each independently H, C_1-C_4haloalkyl or a C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, aryl or heteroaryl group each optionally substituted or R_9 and R_{10} may be taken together with the atom to which they are attached to form a 5- to 7-membered ring optionally containing 1 or 2 additional heteroatoms selected from O, N or S;

R_{11} is H, COR_{12} or an optionally substituted C_1-C_4alkyl group;

R_{12} is a C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, aryl or heteroaryl group each optionally substituted; and

R_{13} is H or a C_1-C_6alkyl, aryl or heteroaryl group each optionally substituted; or a stereoisomer or tautomer thereof.

Claim 32 (New): The composition according to claim 31 wherein formula I has the proviso that R_3, R_4, R_5 and R_6 are not all –H, unless R_1 is halogen.

Claim 33 (New): The composition according to claim 32 wherein formula I has the further proviso that when R_1 is hydrogen, halogen or NH_2, R_2 is C_1–C_4 alkyl, R_3 and R_4 are both halogen and R_5 and R_6 are both hydrogen, then $(R)_n$ cannot be 2,6-dihalo-4-trifluoromethyl.

Claim 34 (New): The composition according to claim 32 wherein R is halogen or haloalkyl and n is 3.

Claim 35 (New): The composition according to claim 34 wherein said compound is selected from the group consisting of:

5-chloro-3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;

3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;

3-(2,2-dichloro-1-methylcyclopropyl)-1-(2,4,6-trichlorophenyl)-1H-pyrazole-4-carbonitrile;

3-(2,2-dichloro-1,3-dimethylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;
3-(2,2-dibromo-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;
3-(2,2-dibromo-1-methylcyclopropyl)-1-(2,4,6-trichlorophenyl)-1H-pyrazole-4-carbonitrile;
3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;
5-chloro-3-(2,2-dibromo-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;
5-amino-3-(2,2-dibromo-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;
5-bromo-3-(2,2-dibromo-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;
5-amino-3-(2,2-dichloro-1-methylcyclopropyl)-1-(2,4,6-trichlorophenyl)-1H-pyrazole-4-carbonitrile;
5-chloro-3-cyclopropyl-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;
5-chloro-3-(2,2-dichloro-1-methylcyclopropyl)-1-(2,4,6-trichlorophenyl)-1H-pyrazole-4-carbonitrile;
5-bromo-3-(2,2-dichloro-1-methylcyclopropyl)-1-(2,4,6-trichlorophenyl)-1H-pyrazole-4-carbonitrile;
5-bromo-3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;
3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-5-nitro-1H-pyrazole-4-carbonitrile;
3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-5-iodo-1H-pyrazole-4-carbonitrile;
3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-5-(dimethylamino)-1H-pyrazole-4-carbonitrile;
3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-5-(diethylamino)-1H-pyrazole-4-carbonitrile;

5-[(cyclopropanecarbonyl)amino]-3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;

N-{4-cyano-5-(2,2-dichloro-1-methyl-cyclopropyl)-2-[2,6-dichloro-4-(trifluoromethyl)-phenyl]-2H-pyrazol-3-yl}-formimidic acid methyl ester;

N-{4-cyano-5-(2,2-dichloro-1-methyl-cyclopropyl)-2-[2,6-dichloro-4-(trifluoromethyl)-phenyl]-2-H-pyrazol-3-yl}-formimidic acid propyl ester;

N-{4-cyano-5-(2,2-dichloro-1-methyl-cyclopropyl)-2-[2,6-dichloro-4-(trifluoromethyl)-phenyl]-2-H-pyrazol-3-yl}-formimidic acid ethyl ester; and

the stereoisomer, the tautomer and the pharmaceutically acceptable salt thereof.